Slingshot members are tracking this event:

FDA points to deficiencies within Axsome's (AXSM) AXS-05 regulatory application. Final decision on AXS-05's regulatory review for Major Depressive Disorder postponed for Aug. 22, 2021

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Axs-05, Major Depressive Disorder